CTIS2023-504179-26-00进行中(未招募)1 期
COmparison of Bleeding Risk between Rivaroxaban andApixaban for the treatment of acute venous thromboembolism
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 2,760
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •? Symptomatic acute VTE (proximal lower extremity DVT or segmental or greater PE) ? Age = 18 years old ? Provide informed consent - Ability to comprehend the Patient Information Leaflet and to provide signed and dated informed consent - Women of childbearing potential must be using effective contraception (see section 5.3 of main protocol) - Negative urine pregnancy test at Visit 1 required for all females including those presenting with oligomenorrhea or amenorrhea who are =55 years (unless permanently sterile)
排除标准
- •Have received > 72 hours of therapeutic anticoagulation, Creatinine clearance < 30 ml/min calculated with the Cockcroft-Gault formula, Use of any other investigational medicinal product within previous 12 weeks, Co-enrolment in another trial of an investigational medicinal product, •Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 of the SmPC for Rivaroxaban or Apixaban, •Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to: oactive bleeding, oactive malignancy, defined as the following: a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or d) a hematologic malignancy not in complete remission, oweight >120 kg, ohepatic disease associated with coagulopathy and clinically relevant bleeding risk oknown liver disease (Child-Pugh B or C), ouse of contraindicated medications (see Section 6.4) oanother indication for long-term anticoagulation (e.g. atrial fibrillation) opregnant* or breastfeeding *As reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care.
研究者
相似试验
招募中
3 期
Efficacy and safety of rivaroxaban and subcutaneous enoxaparin after spinal surgeryIntravenous thromboembolism.Thromboembolism in the puerperiumO88.23IRCT20211109053014N1Esfahan University of Medical Sciences200
招募中
2 期
Efficiency of rivaroxaban and enoxaparin in the prevention of venous thromboembolic eventsSpinal fusion.Osseous stenosis of neural canalM99.3IRCT20120527009878N16Tabriz University of Medical Sciences60
已完成
2 期
Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaqueIRCT20190729044372N1Kermanshah University of Medical Sciences60
已完成
4 期
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous ThromboembolismVenous ThromboembolismNCT03266783Ottawa Hospital Research Institute2,760
已完成
3 期
Effect of Rivrvoxaban on the Prevention of Deep Vein Thrombosis and Pulmonary EmbolismCondition 1: Deep Vein Thrombosis. Condition 2: Pulmonary Embolism.Phlebitis and thrombophlebitis of other deep vessels of lower extremities Deep vein thrombosisI80.2Pulmonary embolismIRCT20181128041781N1Sabzevar University of Medical Sciences50
